Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, the European Federation of Pharmaceutical Industries and Associations warned European Commission officials, with suddenly cheap meds in Greece diverted for sale at higher prices in neighboring EU countries.
Novartis has big plans for its much-anticipated heart failure remedy Entresto. The Swiss drugmaker figures it can parlay impressive trial data on the drug into its biggest launch in years--perhaps ever.
Actors cry and laugh on command, but people who have pseudobulbar affect can't control their crying jags or laughing fits.
In the post-FTC v. Actavis world, cash doesn't have to change hands for a pay-for-delay deal to fall afoul of antitrust law. That's becoming clear as court rulings pile up. And a new U.S. appeals court decision specifically addresses a branded drugmaker's agreement not to launch an authorized generic of its branded drug.
In an apparent sign that federal prosecutors are zeroing in on the pain-drug maker Insys Therapeutics, a Connecticut nurse and top prescriber has pleaded guilty to accepting $83,000 worth of kickbacks from the company.
Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent settlements, it's the first attempt by purchasers to block one of those settlements, the plaintiffs' lawyers said.
The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.
A U.S. judge refused to toss out lawsuits claiming that Eli Lilly & Co. downplayed withdrawal symptoms associated with its blockbuster antidepressant Cymbalta. As Bloomberg reports, Lilly will now have to fight claims that it misled consumers about "brain zaps" and other side effects suffered by people trying to quit using the drug.
AbbVie knows it has to press its case for Viekira Pak if it's going to get--and keep--a sizable share of the hepatitis C market. Today, it unveiled some new data that could help it do just that.
Former Allergan Chairman and CEO David Pyott found himself out of a job when Actavis snapped up his company. He walked away with quite a golden parachute, however--$534 million, says the Orange County Register--and now he has another $5 million to add to his balance sheet.